Body composition after treatment of subclinical hyperthyrodism

Diana Boj-Carceller; Alejandro Sanz-Paris; Johanna Espejo-Nino; Castro-Hernanz Paloma de; Marta Monreal-Villanueva; Diego Alvarez-Ballano; Maria Dolores Abos-Olivares

doi:10.1530/endoabs.37.EP975

EP975

Prev Next

Section Contents Cite

Endocrine Abstracts (2015) 37 EP975 | DOI: 10.1530/endoabs.37.EP975

ECE2015 Eposter Presentations Thyroid (non-cancer) (160 abstracts)

Body composition after treatment of subclinical hyperthyrodism

Diana Boj-Carceller ¹ , Alejandro Sanz-París ¹ , Johanna Espejo-Niño ² , Paloma de Castro-Hernández ¹ , Marta Monreal-Villanueva ¹ , Diego Alvarez-Ballano ¹ & María Dolores Abós-Olivares ²

Err

Author affiliations View ePoster Download ePoster

¹Department of Endocrinology and Nutrition, Hospital Universitario Miguel Servet, Zaragoza, Spain; ²Department of Nuclear Medicine, Hospital Universitario Miguel Servet, Zaragoza, Spain.

Background: Subclinical hyperthyroidism (SHT) is associated with harmful effects on cardiovascular system, bone metabolism and progression to clinical hyperthyroidism. Loss of weight is a common fact in patients with clinical hyperthyroidism and of particular relevance in elderly patients, who are vulnerable to sarcopenia.

Objective: To assess changes in body composition after radioiodine therapy for SHT due to toxic nodular goitre.

Subjects and methods: Prospective controlled cohort study. Patients with persistent SHT due to toxic nodular goitre received a single fixed dose of ¹³¹I (555 MBq). A control group was established with patients who preferred to delay treatment. Body composition (lean mass, fat mass and bone mineral content) was determined by dual-energy X-ray absorptiometry (DEXA) at baseline and 12 months after.

Results: Twenty-nine patients were studied (age 69.5±11.5; 75.9% women; BMI 27.1±5.7 kg/m²; serum thyrotropin (TSH) 0.20±0.21 μUI/ml; serum free thyroxine (T₄) 1.01±0.19 ng/dl), 17 belonging to the treatment group and 12 to the control group. Study groups were comparable. No longitudinal changes in body composition were noted in either group, except for a trend to gain fat mass. However, when individuals with age >65 years were selected, only patients who received radioiodine therapy showed a significant increase in body weight (from 64.1±10.0 to 66.9±9.2 kg), BMI (from 27.3±4.8 to 28.7±4.5 kg/m²), fat mass (from 26.1±8.5 to 27.8±7.9 kg), lean mass (from 36.3±0.4 to 37.4±0.4 kg) and skeletal muscle mass index (SMI) (from 6.0±0.6 to 6.3±0.6 kg/m²).

Conclusions: Treatment of SHT seems to have positive effects on body composition in subjects older than 65 years. Weight gain reflects increases in both fat and lean mass.